Linked Life Data

21331766

Source:http://linkedlifedata.com/resource/pubmed/id/21331766

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2011-5-3
pubmed:abstractText
Lecithin cholesterol acyl transferase (LCAT) is a plasma enzyme that esterifies cholesterol and raises high-density lipoprotein cholesterol, but its role in atherosclerosis is not clearly established. Studies of various animal models have yielded conflicting results, but studies done in rabbits and non-human primates, which more closely simulate human lipoprotein metabolism, indicate that LCAT is likely atheroprotective. Although suggestive, there are also no biomarker studies that mechanistically link LCAT with cardiovascular disease. Imaging studies of patients with LCAT deficiency have also not yielded a clear answer to the role of LCAT in atherosclerosis. Recombinant LCAT, however, is currently being developed as a therapeutic product for enzyme replacement therapy of patients with genetic disorders of LCAT for the prevention and/or treatment of renal disease, but it may also have value for the treatment of acute coronary syndrome.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1534-6242
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
13
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
249-56
pubmed:meshHeading
pubmed:year
2011
pubmed:articleTitle
Lecithin cholesterol acyltransferase: an anti- or pro-atherogenic factor?
pubmed:affiliation
Institutes of Health, National Heart, Lung and Blood Institute, Cardio-Pulmonary Branch, Lipoprotein Metabolism Section, 10 Center Dr Bldg. 10/8N224, Bethesda, MD 20814, USA. roussetx@nhlbi.nih.gov
pubmed:publicationType
Journal Article, Review, Research Support, N.I.H., Intramural